United Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo

United Therapeutics Gets Dual Target Hikes From BofA and Wells Fargo

United Therapeutics (NASDAQ:UTHR) surged more than 12% in pre-market trading on March 30 after positive TETON-1 trial data triggered price target raises from two major Wall Street firms. The results validate a meaningful expansion of Tyvaso’s addressable market beyond pulmonary arterial hypertension into idiopathic pulmonary fibrosis, a condition with significant unmet need and limited treatment options. Ticker Company Firm Old Target New Targe…

United Therapeutics Corporation Announces TETON-1 Pivotal Study of Tyvaso® Meets Primary Endpoint for Treatment of Idiopathic Pulmonary Fibrosis, Exceeding Impressive Treatment Effect Seen in TETON-2

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Mar 30, 2026-